(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.52%.
Longeveron's earnings in 2026 is -$23,474,000.On average, 6 Wall Street analysts forecast LGVN's earnings for 2026 to be -$23,197,321, with the lowest LGVN earnings forecast at -$25,932,794, and the highest LGVN earnings forecast at -$19,750,880. On average, 6 Wall Street analysts forecast LGVN's earnings for 2027 to be -$15,175,818, with the lowest LGVN earnings forecast at -$18,121,712, and the highest LGVN earnings forecast at -$13,390,427.
In 2028, LGVN is forecast to generate -$2,926,765 in earnings, with the lowest earnings forecast at -$17,496,825 and the highest earnings forecast at $12,720,906.